New hope to keep cancer treatment on track: drug trial targets Chemotherapy's dangerous side effect
NCT ID NCT05772546
Summary
This study is testing if a drug called avatrombopag can help patients with gastrointestinal cancers who develop persistently low platelet counts from their chemotherapy. Low platelets can cause dangerous bleeding and force doctors to delay or reduce chemotherapy doses. About 60 participants will be randomly assigned to receive either avatrombopag or a placebo pill for up to seven weeks to see if the drug safely helps raise platelet counts and allows patients to continue their planned cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215, United States
-
Oregon Health and Science University Hospital
Portland, Oregon, 97239, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Washington Fred Hutchinson Cancer Center
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.